The French competition authority, Autorité de la concurrence, has fined the pharmaceutical groups Novartis, Roche and Genentech, a combined €444.85 million for abuse of dominant position to impose the use of the drug Lucentis over its cheaper alternative Avastin in the treatment of age-related macular degeneration (AMD).
Buying a membership today will give you:
To continue reading this article register now.